title: Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
abstract: Omacetaxine mepesuccinate is a protein synthesis inhibitor that causes apoptosis of chronic myeloid leukemia cells without binding to the BCR-ABL tyrosine kinase that is implicated in the pathogenesis of this disease. It has been approved for the treatment of chronic myeloid leukemia in patients with resistance to two or more tyrosine kinase inhibitors and is emerging as an important agent in countering the highly resistant T315I mutation. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of omacetaxine mepesuccinate in the current milieu of tyrosine kinase inhibitor-dominant therapy of chronic myeloid leukemia.
authors.affiliation: Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
authors.forename: V
authors.initials: V
authors.lastname: Narayanan
authors.forename: J A
authors.initials: JA
authors.lastname: Gutman
authors.forename: D A
authors.initials: DA
authors.lastname: Pollyea
authors.forename: A
authors.initials: A
authors.lastname: Jimeno
mesh_terms: D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006248:Harringtonines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000077863:Homoharringtonine; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*
chemical_list: D006248:Harringtonines; D000077863:Homoharringtonine
keywords: Chronic myeloid leukemia; Omacetaxine mepesuccinate; Protein synthesis inhibitor; T315I mutation; Tyrosine kinase inhibitor